Frequently Asked Questions
1. Does everyone get Formula #12 or is there a placebo in the trial?
Everyone receives the actual supplement.
2. How long will the trial last?
The initial trial will last about three weeks for each participant. In our experience, this has been enough time to determine whether it may have a significant impact. While we are tabulating data, and while we await the last person recruited to finish, we will endeavor to supply the supplement throughout this period if the participant wishes (and is obtaining any benefits).
3. What will follow this trial?
If this mini-trial replicates our past experience, we will pursue a 1500 person trial. People on this mini-trial will have priority to join this next larger trial (also no cost) if they wish so that we continue to collect data from ongoing participation.
4. Have there been any side effects?
There have been no side effects from the supplement. It is comprised of well-known and well-tested components which have an excellent safety record. However, we will be monitoring everyone for any potential side effects throughout all trials.
5. How may I benefit from participating?
The supplement might possibly provide a favorable impact on your quality of life. If so, you will be eligible to continue participation at the next trial level without cost.
6. Are there any charges to me?
There are no charges at all. We will pursue funding for the next larger trial so that there is no cost to the participants. Ultimately if the supplement proves valuable, it may be made available for sale at some point in time, as an over-the-counter lower cost supplement, not as a prescription drug.
7. How is the Therapeutics Research Institute (TRI) related to the supplement being tested?
TRI has no financial connection or stake in the supplement in any manner. TRI is paying for the administration of the trial from contributions TRI has received from donors to TRI (an IRS non-profit public charity). It is the purpose of TRI to do this kind of research and possible validation of worthwhile approaches to health care.
8. If I have questions, who do I call?
The trial administrator is Steven Evans, President and Senior Research Scientist for TRI. The TRI offices are shared with the Genetic Services Management, Inc. corporation, a corporation pursuing clinical trials related to potential cancer prevention. To reach Steve Evans, call 402-551-1020 or email to [email protected] [the TRI address is 418 N. 38th St., Omaha, NE 68131 - fax: 402-556-5743].
